In rheumatoid arthritis patients treated for 12 months with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody that rapidly reduces acute phase reactants, C3 and C4 serum levels also decrease [68]. Here, C3 is linked to rheumatoid arthritis.